Cart
sales@molnova.com
KCL-286
CAS No. 1952276-71-9
KCL-286( —— )
Catalog No. M37200 CAS No. 1952276-71-9
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 123 | Get Quote |
|
| 5MG | 187 | Get Quote |
|
| 10MG | 302 | Get Quote |
|
| 25MG | 615 | Get Quote |
|
| 50MG | 984 | Get Quote |
|
| 100MG | 1305 | Get Quote |
|
| 200MG | 1755 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKCL-286
-
NoteResearch use only, not for human use.
-
Brief DescriptionKCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
-
DescriptionAnticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRetinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1952276-71-9
-
Formula Weight334.33
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C=1C=CC(=CC1)C2=NOC(=N2)C=3OC=4C(C3)=C(C=CC4C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..?
molnova catalog
related products
-
Sodium sulfadiazine
Sodium Sulfadiazine is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative.
-
ER 50891
ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.
-
BMS 753
BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
